^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SCRI-huCAR19v1
i
Other names: SCRI-huCAR19v1, second generation 4 1BBζ CD19-Her2tG
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Seattle Children's Hospital
Drug class:
CD19-targeted CAR-T immunotherapy, HER2-targeted CAR-T immunotherapy
Related drugs:
2years
PLAT-02: A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia (clinicaltrials.gov)
P1/2, N=167, Active, not recruiting, Seattle Children's Hospital | Trial completion date: Sep 2035 --> Jul 2036 | Trial primary completion date: Sep 2020 --> Aug 2021
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
Breyanzi (lisocabtagene maraleucel) • SCRI-huCAR19v1
3years
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov)
P1/2, N=16, Active, not recruiting, Seattle Children's Hospital | Suspended --> Active, not recruiting | N=112 --> 16
Clinical • Enrollment closed • Enrollment change • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
SCRI-huCAR19v1 • SCRI-huCAR19v2
over3years
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov)
P1/2, N=112, Suspended, Seattle Children's Hospital | Recruiting --> Suspended
Clinical • Trial suspension • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
SCRI-huCAR19v1 • SCRI-huCAR19v2
over3years
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov)
P1/2, N=112, Recruiting, Seattle Children's Hospital | Active, not recruiting --> Recruiting
Clinical • Enrollment open • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
SCRI-huCAR19v1 • SCRI-huCAR19v2
Share via
